Findings

What do systematic reviews say?

119 questions · 124 findings · 11 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 10 · 8.1%GRADE not reported 4 · 3.2%Very low 27 · 21.8%Low 32 · 25.8%Moderate 27 · 21.8%High 24 · 19.4%

Pregabalin or Gabapentin vs control or placebo medications

Length of critical care stay (hours) · adults undergoing brain surgery

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for the prevention of acute postoperative pain in adults following brain surgery 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pregabalin or Gabapentin vs control or placebo medications

Length of hospital stay · adults undergoing brain surgery

1 finding from 1 review

Pharmacological interventions for the prevention of acute postoperative pain in adults following brain surgery 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 100 participants
Very low

Pregabalin or Gabapentin vs control or placebo medications

Adverse event nausea and vomiting (0 to 24 hours) · adults undergoing brain surgery

Pregabalin or Gabapentin may leads to lower adverse event nausea and vomiting (0 to 24 hours) compared with control or placebo medications (low certainty).

1 finding from 1 review

Pharmacological interventions for the prevention of acute postoperative pain in adults following brain surgery 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 273 participants
Low

Pregabalin 300 mg vs placebo

Pain score · women having medical abortion before 14 weeks' gestation

1 finding from 1 review

Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 107 participants
Low

Pregabalin 300 mg vs placebo

Nausea · women having medical abortion before 14 weeks' gestation

Summary of findings table ‐ Pregabalin 300 mg showed no clear difference in gastrointestinal side effects (nausea) compared with placebo (low certainty).

1 finding from 1 review

Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
OR 0.85 [0.33, 2.19]
1 study · 107 participants
Low

Pregabalin 300 mg vs placebo

Vomiting · women having medical abortion before 14 weeks' gestation

Summary of findings table ‐ Pregabalin 300 mg showed no clear difference in gastrointestinal side effects (vomiting) compared with placebo (low certainty).

1 finding from 1 review

Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
OR 0.76 [0.35, 1.63]
1 study · 107 participants
Low

Pregabalin 300 mg vs placebo

Diarrhoea · women having medical abortion before 14 weeks' gestation

Summary of findings table ‐ Pregabalin 300 mg showed no clear difference in gastrointestinal side effects (diarrhoea) compared with placebo (low certainty).

1 finding from 1 review

Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
OR 0.82 [0.38, 1.76]
1 study · 107 participants
Low

Pregabalin 300 mg vs placebo

Complete abortion rate ‐ not reported · women having medical abortion before 14 weeks' gestation

The review found no eligible studies for this question.

1 finding from 1 review

Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pregabalin 300 mg vs placebo

Induction to expulsion interval ‐ not reported · women having medical abortion before 14 weeks' gestation

The review found no eligible studies for this question.

1 finding from 1 review

Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pregabalin 300 mg vs placebo

Unscheduled contact with care ‐ not reported · women having medical abortion before 14 weeks' gestation

The review found no eligible studies for this question.

1 finding from 1 review

Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pregabalin 300 mg vs placebo

Patient satisfaction with analgesia ‐ not reported · women having medical abortion before 14 weeks' gestation

Summary of findings table ‐ Pregabalin 300 mg showed no clear difference in patient satisfaction with analgesia compared with placebo (low certainty).

1 finding from 1 review

Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
OR 0.97 [0.42, 2.21]
1 study · 104 participants
Low

Pregabalin 300 mg vs placebo

Patient satisfaction with abortion care overall ‐ not reported · women having medical abortion before 14 weeks' gestation

Summary of findings table ‐ Pregabalin 300 mg showed no clear difference in patient satisfaction with abortion care overall compared with placebo (low certainty).

1 finding from 1 review

Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
OR 1.84 [0.8, 4.22]
1 study · 105 participants
Low

Pregabalin vs placebo

Self‐reported pain relief ‐ NPSI: ranges from 0 to 100. Higher scores are indicative of neuropathic pain. · adults and children with sickle cell disease experiencing neuropathic pain

1 finding from 1 review

Interventions for treating neuropathic pain in people with sickle cell disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
Very low

Self‐reported pain relief ‐ S‐LANSS: Possible total scores range from 0 to 24, and a score of 12 or higher is indicative of neuropathic pain. · adults and children with sickle cell disease experiencing neuropathic pain

1 finding from 1 review

Interventions for treating neuropathic pain in people with sickle cell disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
Very low

Pregabalin vs placebo

Patient Global Impression of Change · adults and children with sickle cell disease experiencing neuropathic pain

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating neuropathic pain in people with sickle cell disease 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pregabalin vs placebo

Time to improvement of symptoms · adults and children with sickle cell disease experiencing neuropathic pain

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating neuropathic pain in people with sickle cell disease 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pregabalin vs placebo

QoL · adults and children with sickle cell disease experiencing neuropathic pain

1 finding from 1 review

Interventions for treating neuropathic pain in people with sickle cell disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
Very low

Pregabalin vs placebo

Quality of sleep · adults and children with sickle cell disease experiencing neuropathic pain

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating neuropathic pain in people with sickle cell disease 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pregabalin vs placebo

Treatment‐related adverse effects · adults and children with sickle cell disease experiencing neuropathic pain

It is very uncertain whether summary of findings ‐ Pharmacological intervention (pregabalin) changes treatment‐related adverse effects compared with placebo (very low certainty).

1 finding from 1 review

Interventions for treating neuropathic pain in people with sickle cell disease 2019 · Cochrane Headline outcomes only
RR 1.33
1 study · 22 participants
Very low